Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Brunei Darussalam

Brunei Darussalam

The revenue in the Other Vaccines market of Brunei Darussalam is estimated to reach US$1.62m in 2024.
It is anticipated that the revenue will display an annual growth rate (CAGR 2024-2029) of 9.92%, leading to a market volume of US$2.60m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$24,730.00m in 2024.
Brunei Darussalam's growing healthcare infrastructure and government initiatives have led to an increasing demand for other vaccines in the country.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Brunei Darussalam has seen steady growth in recent years.

Customer preferences: Brunei Darussalam has a high vaccination rate, with many citizens opting to receive vaccines for various illnesses. The government has also implemented a strong vaccination program for children, which has increased awareness and demand for vaccines in the country.

Trends in the market: The Other Vaccines market in Brunei Darussalam has seen an increase in demand for vaccines that protect against illnesses such as meningitis and pneumonia. This is due to a growing awareness of the importance of preventative measures and a desire to protect against serious illnesses. Additionally, there has been a trend towards vaccinations for travel purposes, with more citizens opting to receive vaccines before traveling abroad.

Local special circumstances: Brunei Darussalam has a small population and a high standard of living, which has allowed for a strong healthcare system and increased access to vaccines. The government has also implemented policies to promote healthy living and preventative healthcare measures, which has contributed to the growth of the Other Vaccines market.

Underlying macroeconomic factors: The economy of Brunei Darussalam is heavily reliant on the oil and gas industry, which has allowed for high levels of government spending on healthcare and social services. This has contributed to the growth of the Other Vaccines market, as the government has invested in preventative healthcare measures and made vaccines more accessible to the general population. Additionally, the country has a high level of education and awareness, which has led to a greater understanding of the importance of vaccines and preventative healthcare measures.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.